Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids

Internal Medicine Journal

Volumn 41, Issue 7, 2011, Pages 525-536

  Domingo, C ^a,b   Moreno, A ^a,b   Mirapeix, R ^c  

^a Servicio de Oncología Médica   (Spain)

^b Departments of Medicine   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

GINA step five; Immunomodulatory drug; Immunosuppressive drug; Oral corticosteroid asthma; Severe asthma; Steroid sparing agent

Indexed keywords

AZATHIOPRINE; BECLOMETASONE; COLCHICINE; CYCLOSPORIN A; DAPSONE; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; OMALIZUMAB; PLACEBO; PREDNISONE; TROLEANDOMYCIN;

ALOPECIA; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SCREENING; ECZEMA; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOMODULATION; METHOTREXATE; WORLD HEALTH;

EID: 79960452082     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02481.x     Document Type: Article

References (77)

1. Jaffuel D, Mathieu M, Chanez P. Corticosteroid-resistant asthma: basic aspects [article in French]. Presse Med 1999; 28: 709-17.
2. Nimmagadda SR, Spahn JD, Leung DY, Szefler SJ. Steroid-resistant asthma: evaluation and management. Ann Allergy Asthma Immunol 1996; 77: 345-55.
3. Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med 1990; 112: 577-81.
4. Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336: 137-40.
5. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-93.
6. International Consensus Report on diagnosis and treatment of asthma. National Heart, Lung and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication number 92-3091, March 1992. Eur Respir J 1992; 5: 601-41.
7. Comet R, Domingo C, Larrosa M, Morón A, Rué M, Amengual MJ etal. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. a double-blind, randomized, placebo-controlled study. Respir Med 2006; 100: 411-19.
8. Arkins JA, Hirsch SR. Clinical effectiveness of 6-mercaptopurine in bronchial asthma. J Allergy 1966; 37: 90-5.
9. Kaiser HB, Beall GN. Azathioprine (imuran) in chronic asthma. Ann Allergy 1966; 24: 369-70.
10. Arkins JA. The effect of 6-mercaptopurine on spontaneous canine asthma. Allergy 1966;44: 108.
11. Dykewicz MS. Newer and alternative non-steroidal treatments for asthmatic inflammation. Allergy Asthma Proc 2001; 22: 11-15.
12. Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med 2008; 102: 1499-510.
13. Charous BL. Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma. Ann Allergy 1990; 65: 53-8.
14. Roberts JA, Gunnerberg A, Elliott JA, Thomson MD. Hydroxychloroquine in steroid dependent asthma. Pulm Pharmacol 1988; 1: 59-61.
15. Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves airflow and lowers circulating IgE. J Allergy Clin Immunol 1998; 102: 198-203.
16. Schwartz YA, Kivity S, Ilfeld DN etal. A clinical and immunologic study of colchicine in asthma. Allergy Clin Immunol 1990; 85: 578.
17. Fish JE, Peters SP, Chambers CV, McGeady SJ, Epstein KR, Boushey HA etal. An evaluation of colchicine as an alternative to inhaled corticosteroids in moderate asthma. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Am J Respir Crit Care Med 1997; 156: 1165-71.
18. Spector S, Katz F, Farr R. Troleandomycin: effectiveness in steroid dependent asthma and bronchitis. J Allergy Clin Immunol 1974; 54: 367-79.
19. Nelson HS, Hamilos DL, Corsello PR, Levesaue NV, Buchmeier AD, Bucher BL. A double-blind study of troleandomycin and prednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993; 147: 398-404.
20. Siracusa A, Brugnami G, Fiordi T, Areni S, Sverini C, Marabini A. Troleandomycin in the treatment of difficult asthma. J Allergy Clin Immunol 1993; 92: 677-82.
21. Ball BD, Hill MR, Brenner M, Sanks R, Szefler SJ. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy 1990; 65: 37-45.
22. Kamada AK, Hill MR, Iklé DN, Brenner AM, Szefler SJ. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993; 91: 873-82.
23. Evans DJ, Cullinan P, Geddes DM, Walters EH, Jones PW, Milan SJ. Troleandomycin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD00298. DOI: 10.1002/14651858.CD002987.
24. Mullarkey M. Immunosuppressive therapy for asthma. Allergy Proc 1995; 16: 81-4.
25. Berlow BA, Liebhaber MI, Dyer Z, Spiegel TM. The effect of dapsone in steroid dependent asthma. J Allergy Clin Immunol 1991; 87: 710-15.
26. Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991; 87:976-83.
27. Landwehr LP, Jeppson JD, Katlan MG etal. Benefits of high-dose IV immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998; 114: 1349-56.
28. Kishiyama JL, Valacer D, Cunningham-Rundles C. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 1999; 91: 126-33.
29. Jakobsson T, Croner S, Kjellman N-IM, Petterson A, Vasella C, Björksten B. Slight sparing effect of IV immunoglobulin in children and adolescents with moderately severe asthma. Allergy 1994; 49: 413-20.
30. Hodges NG, Brewis RAL, Howell1 JBL. An evaluation of azathioprine in severe chronic asthma. Thorax 1971; 26: 734-9.
31. Asmundson T, Kilburn KH, Laszlo J, Kcrock CJ. Immunosuppressive therapy of asthma. J Allergy 1971; 47: 136-47.
32. Klaustermeyer WB, Noritake DJ, Kwong FK. Chrysotherapy in the treatment of corticosteroid-dependent asthma. J Allergy Clin Immunol 1987; 79: 720-5.
33. Nierop G, Gijzel WP, Bell EH, Zwinderman AH, Dijkman JH. Auranofin in the treatment of steroid-dependent asthma: a double blind study. Thorax 1992; 47: 349-54.
34. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B and participants of Auranofin Multicentre Drug trial. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol 1996; 98: 317-24.
35. Szczeklik A, Nizankowska E, Dwoerski R, Domagala B, Pinis G. Cyclosporin for steroid-dependent asthma. Allergy 1991; 46: 312-15.
36. Mungan D, Misirligil Z, Sin B, Kaya A, Demirel Y, Gürbüz L. Cyclosporin in steroid dependent asthma. Allergol Immunopathol 1995; 23: 202-6.
37. Coren MR, Rosenthal M, Bush A. The use of cyclosporin in corticosteroid dependent asthma. Arch Dis Child 1997; 77: 522.
38. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339: 324-8.
39. Nizankowska E, Soja J, Pinis G. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995; 8: 109-1099.
40. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153: 509-14.
41. Mullarkey MF, Webb DR, Pardee NE. Methotrexate in the treatment of steroid-dependent asthma. Ann Allergy 1986; 56: 347-50.
42. Domingo C, Comet R, Bosque M, Moron A, Monton C. Efficiency of methotrexate in the treatment of cortico-dependent asthmatic patients. Rev Clin Esp 1999; 199: 142-6.
43. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel CE. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. N Engl J Med 1988; 318: 603-7.
44. Hedman J, Seideman P, Albertioni F, Stenius-Aarniala B. Controlled trial of methotrexate in patients with severe chronic asthma. Eur J Clin Pharmacol 1996; 49: 347-9.
45. Erzurum SC, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, Martin RJ etal. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. Ann Intern Med 1991; 114: 353-60.
46. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1991; 88: 208-12.
47. Trigg CJ, Davies RJ. Comparison of methotrexate 30mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study. Respir Med 1993; 8: 211-16.
48. Taylor DR, Flannery EM, Herbison GP. Methotrexate in the management of severe steroid dependent asthma. N Z Med J 1993; 106: 409-11.
49. Stewart GE 2nd, Diaz JD, Lockey RF, Seleznick MJ, Trudeau WL, Ledford DK. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma. J Allergy Clin Immunol 1994; 94: 482-9.
50. Coffey MJ, Sanders G, Eschenbacher WL, Tsien A, Ramesh S, Weber RW etal. The role of methotrexate in the management of steroid-dependent asthma. Chest 1994; 105: 117-21.
51. Kanzow G, Nowak D, Magnussen H. Short term effect of methotrexate in severe steroid-dependent asthma. Lung 1995; 173: 223-31.
52. Ogirala RG, Sturm TM, Aldrich TK, Meller FF, Pacia EB, Keane AM etal. Single, high-dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double-blind study. Am J Respir Crit Care Med 1995;152: 1461-6.
53. Aaron SD, Dales RE, Pham B. Management of steroid-dependent asthma with methotrexate: a meta-analysis and randomised clinical trials. Respir Med 1998; 92: 1059-65.
54. Marin MG. Low-dose methotrexate spares steroid usage in steroid-dependent chronic asthmatic patients: a meta-analysis. Chest 1997; 112:29-3353.
55. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000; CD000391.
56. Domingo C, Moreno A, Amengual MJ, Comet R, Luján M. Twelve years' experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin 2009; 25: 367-94.
57. Corrigan CJ, Shiner RJ, Shakur BH, Ind PW. Methotrexate therapy of oral corticosteroid-dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy. Clin Exp Allergy 2005; 35: 579-84.
58. Meshkin B, Blum K. Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics. Drug Metab Lett 2007; 1: 55-60.
59. Wallace CA, Sherry DD, Mellins ED, Aiken RP. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993; 20: 118-22.
60. Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994; 47: 25-50.
61. Kremer JM. Methotrexate update. Scand J Rheumatol 1996; 25: 341-4.
62. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163-72.
63. Buckley LM, Leib ES, Cartlaro KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997; 24: 1489-94.
64. Polosa R. An overview of chronic severe asthma. Intern Med J 2008; 38: 190-8.
65. Domingo C, Pacheco A, Hinojosa M, Bosque M. The relevance of IgE in the pathogenesis of allergy: the effect of an anti-IgE drug in asthma and other diseases. Recent Pat Inflamm Allergy Drug Discov 2007; 1: 151-64.
66. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22: 470-7.
67. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M etal. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: 336.
68. Lemanske RF, Nayak A, McAlary M, Everhard F, Fowter-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002; 110: e55.
69. Busse W, Corren J, Lanier BQ etal. Omalizumab, anti-IGE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90.
70. Soler M, Matz J, Townley R etal. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 739-40.
71. Holgate ST, Chuchalin AG, Hebert J etal. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632-8.
72. Humbert M, Beasley R, Ayres J etal. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-16.
73. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S etal. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbation and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-8.
74. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; 2: CD003559.
75. Domingo Ch, Moreno A, Amengual MJ, Monton C, Suárez D, Pomares X. Omalizumab in the management of oral corticosteroid-dependent IgE-mediated asthma patients. Curr Med Res Opin 2011; 27: 45-53.
76. Haldar P, Brightling CE, Hargadon B etal. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
77. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. NIH publication number 95-3659. [cited October 15 2010]. Available from URL: